Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Cardiology/Vascular Diseases | Family Medicine
Disease Category: Diabetes and Hypertension
Location: United States, CA
Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
Multicenter, randomized, double blind, placebo controlled 2~arm study designed to evaluate the cardiovascular safety of alogliptin compared with placebo in addition to standard of care, in subjects with type II diabetes mellitus (T2DM), and acute coronary syndrome (ACS).
Patient Inclusion Criteria:
Men & women diagnosed with type 2 diabetes mellitus who are taking one or more anti~diabetic medications. Must have a HG A1c of 6.5-11.0 inclusive at screening. Also, patients must have diagnosis of ACS within 15-90 days prior to randomization.
Patient Exclusion Criteria:
Patient has sign of or is diagnosed with type I diabetes mellitus or latent autoimmune diabetes. Patient has unstable cardiovascular disorder including heart failure, angina, cardiac arrhythmias, critical valvular heart disease, severe hypertension at screening.
Nasra Hashmi, Research Specialist
Coastal Multi-Specialty Research
2621 S. Bristol St.
Suite 108 A
Santa Ana, CA 92704
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these